aleniglipron vs CX11

NCT06703021 · Phase 2 · completed

The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT07011797 · Phase 2 · completed

In this randomized, double-blind, placebo-controlled Phase 2 trial, 250 adults with obesity were assigned to CX11 at several doses or placebo for 26 weeks, with follow-up to 36 weeks. The company reported that the trial's weight-loss primary endpoints were met, with weight loss reaching up to 11.5% by week 36 and continuing without a plateau; gastrointestinal side effects were the most common safety finding.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.